MARLBOROUGH, Mass.--(BUSINESS WIRE)--Sepracor Inc. (Nasdaq: SEPR) today announced the presentation of posters of clinical data from studies of XOPENEX HFA® (levalbuterol tartrate) Inhalation Aerosol and XOPENEX® (levalbuterol HCl) Inhalation Solution at CHEST 2006, the annual meeting of the American College of Chest Physicians (ACCP), in Salt Lake City.
